Lakeside (QNME)
Distributes infusion, specialty-prescription, and medical-nutrition products through China's healthcare channels.
Something off on this page? Send us feedback.
Distributes infusion products, specialty prescription drugs, and medical-nutrition products in China, earning product-sale revenue by sourcing from manufacturers and selling through agents to healthcare customers. The business is the holding company's sole disclosed revenue-producing continuing operation.
Runs a China-based pharmaceutical-distribution business through Hupan Pharmaceutical, sourcing infusion products, specialty prescription drugs, and medical-nutrition products from manufacturers. Products are stored in designated warehouses and sold and delivered, primarily through agents, to distributors, hospitals, clinics, and other healthcare providers.
Became the sole disclosed revenue-producing continuing operation after the former U.S. cross-border logistics business was transferred. Operations depend on access to manufacturers, agents, healthcare customers, Chinese pharmaceutical demand, and a specialized pharmaceutical-distribution license; the parent reports in U.S. dollars while the operating business uses renminbi. The current Nasdaq name and ticker change are not accompanied in opened primary sources by a documented product or operating strategy.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Mar 31, 2026Cash & short-term investments $1.3M · Total debt $561.6K · Total assets $17.8M · Shareholders' equity $13.6M
- Revenue
- $1.3M
- Operating income
- −$1.6M
- Net income
- −$1.5M
No dividends on record.
No ownership filings on record for this listing.
Not reported.